Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.

about

Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.

Item

http://www.wikidata.org/entity/Q43930995

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Treatment of high-risk aggress ...... e R-MegaCHOP-ESHAP-BEAM Trial.

@en

Treatment of high-risk aggress ...... e R-MegaCHOP-ESHAP-BEAM Trial.

@nl

type

Item

label

Treatment of high-risk aggress ...... e R-MegaCHOP-ESHAP-BEAM Trial.

@en

Treatment of high-risk aggress ...... e R-MegaCHOP-ESHAP-BEAM Trial.

@nl

prefLabel

Treatment of high-risk aggress ...... e R-MegaCHOP-ESHAP-BEAM Trial.

@en

Treatment of high-risk aggress ...... e R-MegaCHOP-ESHAP-BEAM Trial.

@nl

P1476

Treatment of high-risk aggress ...... he R-MegaCHOP-ESHAP-BEAM Trial

@en

P2093

Alice Sýkorová

http://www.w3.org/2001/XMLSchema#string

Czech Lymphoma Study Group

http://www.w3.org/2001/XMLSchema#string

Ingrid Bolomská

http://www.w3.org/2001/XMLSchema#string

Ingrid Vášová

http://www.w3.org/2001/XMLSchema#string

Jan Pirnos

http://www.w3.org/2001/XMLSchema#string

Jana Přibylová

http://www.w3.org/2001/XMLSchema#string

Kateřina Kubáčková

http://www.w3.org/2001/XMLSchema#string

Lucie Burešová

http://www.w3.org/2001/XMLSchema#string

Milan Matuška

http://www.w3.org/2001/XMLSchema#string

Pavel Klener

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.

Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study.

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma

P304

57-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2014.904509

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24628294

http://www.w3.org/2001/XMLSchema#string